Form 4: Phibro Animal Health CEO's Entity Sells PAHC Shares

Phibro Animal Health Corp's President and CEO, Jack Bendheim, and BFI Co., LLC, reported sales of Class A Common Stock totaling 18,899 shares under a Rule 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC (a 10% Owner over which Mr. Bendheim has voting and dispositive power), reported sales of Class A Common Stock.
• BFI Co., LLC sold a total of 18,899 shares of Class A Common Stock across three transactions between October 22, 2025, and October 24, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Weighted average sale prices for the transactions ranged from $40.1796 to $41.749 per share.
• Following these transactions, BFI Co., LLC beneficially owns 55,000 shares indirectly, and Jack Bendheim directly owns 16,840 shares.

Sentiment

Score: 5

Explanation: The filing reports pre-planned insider sales under a Rule 10b5-1 plan, which are routine and do not necessarily indicate a change in management's outlook, but do reduce insider ownership. This is generally considered neutral without further context.

Negatives

• The reduction in indirect beneficial ownership by 18,899 shares through sales by BFI Co., LLC, an entity over which the CEO exercises control, represents a decrease in insider holdings.

Future Outlook

No forward-looking statements or guidance were provided in this filing, as it pertains solely to insider transactions.

Industry Context

This filing reports company-specific insider transactions and does not contain information related to broader industry trends or competitors.

Related Party Transactions

• Sales of Class A Common Stock by BFI Co., LLC, an entity over which Jack Bendheim, the President and CEO, Director, and 10% Owner, exercises voting and dispositive power. Mr. Bendheim disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may view the reduction in insider ownership, even if pre-planned, with slight caution, though the Rule 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

The filing details pre-planned insider sales by the CEO and an affiliated entity under a Rule 10b5-1 trading plan. Such transactions are often for personal financial planning or diversification and do not typically signal a change in the company's fundamental prospects. Without additional financial or operational data, a 'hold' recommendation is appropriate as this filing alone does not provide a basis for a significant change in investment thesis.

Keywords

PHIBRO ANIMAL HEALTH, PAHC, Jack Bendheim, BFI Co., LLC, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director, 10% Owner